3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Hepatocellular
4
Esophageal Neoplasms
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pinealoma
1
Pancreatic Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Locally Advanced Rectal Adenocarcinoma
1
Locally Advanced Cervical Carcinoma
1
Liver Neoplasms
1
Liver Diseases
1
Hematologic Neoplasms
1
Gastric Cancer With Liver Metastases
1
Endometrial Neoplasms
1
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
pembrolizumab
5
cabozantinib
5
Everolimus
5
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
Etoposide
2
Cisplatin
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
telotristat ethyl
1
surufatinib
1
repotrectinib
1
peposertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Immunotherapy
×
90 days
×
Clear all
No trials found.